Publication date: Jan 02, 2020
Advanced phenotyping of cardiovascular diseases has evolved with the application of high-resolution omics screening to populations enrolled in large-scale observational and clinical trials. This strategy has revealed that considerable heterogeneity exists at the genotype, endophenotype, and clinical phenotype levels in cardiovascular diseases, a feature of the most common diseases that has not been elucidated by conventional reductionism. In this discussion, we address genomic context and (endo)phenotypic heterogeneity, and examine commonly encountered cardiovascular diseases to illustrate the genotypic underpinnings of (endo)phenotypic diversity. We highlight the existing challenges in cardiovascular disease genotyping and phenotyping that can be addressed by the integration of big data and interpreted using novel analytical methodologies (network analysis). Precision cardiovascular medicine will only be broadly applied to cardiovascular patients once this comprehensive data set is subjected to unique, integrative analytical strategies that accommodate molecular and clinical heterogeneity rather than ignore or reduce it.
Leopold, J.A., Maron, B.A., and Loscalzo, J. The application of big data to cardiovascular disease: paths to precision medicine. 06090. 2020 J Clin Invest (130):1.
- Big Data, Health Informatics, and the Future of Medicine
- Precision Medicine: Addressing the Challenges of Sharing, Analysis, and Privacy at Scale.
- Use of >100,000 NHLBI Trans-Omics for Precision Medicine (TOPMed) Consortium whole genome sequences improves imputation quality and detection of rare variant associations in admixed African and Hispanic/Latino populations.
- Advancing functional and translational microbiome research using meta-omics approaches.
- Dynamically characterizing individual clinical change by the steady state of disease-associated pathway.
- PROMO: an interactive tool for analyzing clinically-labeled multi-omic cancer datasets.